Get the Stockscreener App
12.01
0.21%
-0.005
Aurinia Pharmaceuticals Inc stock is traded at $12.01, with a volume of 352.66K.
It is down -0.21% in the last 24 hours and up +39.04% over the past month.
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.
See More
Previous Close:
$12.01
Open:
$11.89
24h Volume:
352.66K
Relative Volume:
0.19
Market Cap:
$1.58B
Revenue:
$260.11M
Net Income/Loss:
$60.64M
P/E Ratio:
27.92
EPS:
0.43
Net Cash Flow:
$92.29M
1W Performance:
-0.87%
1M Performance:
+39.04%
6M Performance:
+51.13%
1Y Performance:
+81.87%
1-Day Range:
$11.74
$12.01
1-Week Range:
$11.74
$12.53
52-Week Range:
$6.42
$12.53
Aurinia Pharmaceuticals Inc Stock (AUPH) Company Profile
Name
Aurinia Pharmaceuticals Inc
Sector
Industry
Phone
250-744-2487
Address
#140, 14315 - 118 AVENUE, EDMONTON, BC
Compare AUPH with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AUPH
Aurinia Pharmaceuticals Inc
|
11.98 | 1.61B | 260.11M | 60.64M | 92.29M | 0.43 |
|
VRTX
Vertex Pharmaceuticals Inc
|
396.25 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
602.36 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
465.66 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
664.80 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
310.83 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Aurinia Pharmaceuticals Inc Stock (AUPH) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-30-25 | Resumed | H.C. Wainwright | Buy |
| Nov-04-22 | Downgrade | Oppenheimer | Outperform → Perform |
| May-05-22 | Resumed | Cantor Fitzgerald | Overweight |
| Dec-10-21 | Upgrade | Oppenheimer | Perform → Outperform |
| Oct-28-21 | Downgrade | Oppenheimer | Outperform → Perform |
| Jan-25-21 | Reiterated | H.C. Wainwright | Buy |
| Nov-03-20 | Reiterated | H.C. Wainwright | Buy |
| Jun-17-20 | Initiated | BTIG Research | Buy |
| May-05-20 | Initiated | Cowen | Outperform |
| Jan-10-20 | Initiated | Jefferies | Buy |
| Dec-16-19 | Reiterated | H.C. Wainwright | Buy |
| Mar-16-18 | Reiterated | Cantor Fitzgerald | Overweight |
| Feb-08-18 | Initiated | RBC Capital Mkts | Outperform |
| Oct-30-17 | Reiterated | H.C. Wainwright | Buy |
| May-18-17 | Reiterated | H.C. Wainwright | Buy |
| Apr-11-17 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-22-17 | Reiterated | FBR & Co. | Outperform |
| Dec-30-16 | Reiterated | H.C. Wainwright | Buy |
| Aug-17-16 | Reiterated | H.C. Wainwright | Buy |
| Jun-30-16 | Initiated | H.C. Wainwright | Buy |
| May-08-15 | Initiated | MLV & Co | Buy |
View All
Aurinia Pharmaceuticals Inc Stock (AUPH) Latest News
Published on: 2025-08-21 04:00:48 - newsyoung.net
Aurinia Pharmaceuticals Reports Strong Q2 2025 Financial Results and Expands Share Repurchase Plan - MSN
Why is Aurinia Pharmaceuticals Inc. stock going down2025 Growth vs Value & Capital Protection Trading Alerts - thegnnews.com
There's No Escaping Aurinia Pharmaceuticals Inc.'s (NASDAQ:AUPH) Muted Revenues Despite A 29% Share Price Rise - 富途牛牛
Aurinia Pharmaceuticals stock hits 52-week high at 11.81 USD - Investing.com
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Q2 2025 Earnings Call Transcript - MSN
Can machine learning forecast Aurinia Pharmaceuticals Inc. recoveryShort Squeeze Opportunities with Indicators - Newser
Zurcher Kantonalbank Zurich Cantonalbank Acquires 8,390 Shares of Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) - Defense World
Full technical analysis of Aurinia Pharmaceuticals Inc. stockFree Early Entry Tips With Low Risk Zone - Newser
What data driven models say about Aurinia Pharmaceuticals Inc.’s futureFree Expert Verified Stock Trade Ideas - Newser
Will Aurinia Pharmaceuticals Inc. stock go up soonHigh Conviction Stock Long-Term Summary - Newser
Is Aurinia Pharmaceuticals Inc. stock ready for a breakoutHigh Probability Trade Outcome Prediction - Newser
Aurinia Pharma: The Easiest Money May Have Been Made (Rating Downgrade) (NASDAQ:AUPH) - Seeking Alpha
Aurinia (AUPH) Q2 Revenue Jumps 22% - AOL.com
Day 6 of Gains Streak for Aurinia Pharmaceuticals Stock with 32% Return (vs. 30% YTD) [8/5/2025] - Trefis
Major Moves in Aurinia Pharmaceuticals Stock: Insider Trading Unveiled - TipRanks
Aurinia Pharma director Tang buys $13.59m in shares - Investing.com India
Aurinia Pharma director Tang buys $13.59m in shares By Investing.com - Investing.com Canada
Aurinia Pharmaceuticals Reaches Analyst Target Price - Nasdaq
Aurinia Pharmaceuticals (NASDAQ:AUPH) Reaches New 12-Month High on Analyst Upgrade - Defense World
Aurinia (AUPH) Upgraded to Buy: Here's What You Should Know - Yahoo Finance
Aurinia Pharmaceuticals stock hits 52-week high at 10.74 USD By Investing.com - Investing.com South Africa
Aurinia Pharmaceuticals stock hits 52-week high at 10.74 USD - Investing.com
Research Analysts Set Expectations for AUPH FY2026 Earnings - Defense World
Aurinia Pharmaceuticals: Strong Financial Performance and Promising Pipeline Drive Buy Rating - TipRanks
What is Leerink Partnrs’ Forecast for AUPH Q1 Earnings? - Defense World
What are the latest earnings results for Aurinia Pharmaceuticals Inc.Unprecedented profit potential - Jammu Links News
Published on: 2025-08-04 03:37:38 - Jammu Links News
What analysts say about Aurinia Pharmaceuticals Inc. stockCapitalize on emerging investment opportunities - Jammu Links News
What is the risk reward ratio of investing in Aurinia Pharmaceuticals Inc. stockBuild a portfolio that outperforms the market - Jammu Links News
Is it the right time to buy Aurinia Pharmaceuticals Inc. stockAchieve superior capital gains with smart trades - Jammu Links News
Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Just Beat EPS By 9.1%: Here's What Analysts Are Forecasting For This Year - Yahoo Finance
Aurinia raises 2025 revenue outlook to $270M as LUPKYNIS accelerates market penetration - MSN
What catalysts could drive Aurinia Pharmaceuticals Inc. stock higher in 2025Unlock rapid growth potential in your portfolio - Jammu Links News
What drives Aurinia Pharmaceuticals Inc. stock priceFree Stock Market Mentorship - Jammu Links News
Should I hold or sell Aurinia Pharmaceuticals Inc. stock in 2025Free Investment Portfolio Suggestions - Jammu Links News
Aurinia Pharmaceuticals Reports Q2 EPS Beat, Analysts Raise 2025 Estimates - AInvest
What are the technical indicators suggesting about Aurinia Pharmaceuticals Inc.Rapid growth opportunities - Jammu Links News
What is Aurinia Pharmaceuticals Inc. company’s growth strategyFastest-growing stock picks - Jammu Links News
How does Aurinia Pharmaceuticals Inc. generate profit in a changing economyRetirement Planning Forecasts For Consistent Profits - jammulinksnews.com
Aurinia Pharmaceuticals (AUPH): A High-Growth Biopharma Play with Strong Earnings Momentum and Strategic Pipeline Expansion - AInvest
Aurinia Pharmaceuticals Second Quarter 2025 Earnings: Beats Expectations - uk.finance.yahoo.com
Published on: 2025-08-02 11:34:23 - beatles.ru
Aurinia Pharmaceuticals (NASDAQ:AUPH) Trading 6.1% Higher After Analyst Upgrade - Defense World
Q2 Earnings Estimate for AUPH Issued By HC Wainwright - Defense World
Aurinia Pharmaceuticals Inc. Added to High Probability Setup ListTechnical Entry Strategy for Beginners Explained - metal.it
RBC Raises Price Target on Aurinia Pharmaceuticals to $9 From $8, Keeps Outperform, Speculative Risk - MarketScreener
Aurinia 2025 Q2 Earnings Robust Net Income Growth at 2879.6% - AInvest
Aurinia Pharmaceuticals Inc (AUPH) Q2 2025 Earnings Call Highlights: Strong Revenue Growth and ... By GuruFocus - Investing.com Canada
Aurinia Pharmaceuticals (NASDAQ:AUPH) Earns Buy Rating from HC Wainwright - Defense World
Equities Analysts Issue Forecasts for AUPH Q1 Earnings - Defense World
Aurinia Pharmaceuticals Inc Stock (AUPH) Financials Data
Revenue
Net Income
Cash Flow
EPS
Aurinia Pharmaceuticals Inc Stock (AUPH) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| TANG KEVIN | Director |
Aug 05 '25 |
Buy |
11.68 |
200,000 |
2,336,000 |
11,329,500 |
| TANG KEVIN | Director |
Aug 04 '25 |
Buy |
11.34 |
100,000 |
1,134,000 |
11,129,500 |
| Keenan Greg | Chief Medical Officer |
Aug 01 '25 |
Sale |
10.50 |
20,000 |
210,000 |
133,484 |
| Keenan Greg | Chief Medical Officer |
Mar 07 '25 |
Sale |
8.23 |
8,305 |
68,350 |
153,484 |
| Greenleaf Peter | Chief Executive Officer |
Mar 03 '25 |
Sale |
8.00 |
195,593 |
1,564,744 |
1,953,892 |
| Greenleaf Peter | Chief Executive Officer |
Mar 04 '25 |
Sale |
7.92 |
164,947 |
1,306,380 |
1,788,945 |
| Keenan Greg | Chief Medical Officer |
Mar 03 '25 |
Sale |
8.00 |
12,239 |
97,912 |
161,789 |
| Miller Joseph M | Chief Financial Officer |
Mar 03 '25 |
Sale |
8.00 |
61,859 |
494,872 |
633,515 |
| Miller Joseph M | Chief Financial Officer |
Mar 04 '25 |
Sale |
7.92 |
56,154 |
444,740 |
577,361 |
| Robertson Stephen P. | EVP, General Counsel |
Mar 03 '25 |
Sale |
8.00 |
64,872 |
518,976 |
566,883 |
1.08%
0.57%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):